 REDWOOD CITY, Calif. BOSTON--BUSINESS WIRE--Adicet Bio, Inc. Nasdaq: ACET, a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor CAR T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in June. Details of the events are as follows: Truist Securities Cell Therapy Symposium, Symposia-cel, June 28, 2022 Chen Schor, President CEO, will part 